Pixatimod is under clinical development by Zucero Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pixatimod’s likelihood of approval (LoA) and phase transition for Metastatic Adenocarcinoma of The Pancreas took place on 11 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pixatimod Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pixatimod overview

Pixatimod (PG-545) is under development for the treatment of advanced solid tumors including microsatelite stable metastatic colorectal cancer, non-small cell lung cancer, metastatic colorectal cancer and melanoma, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, dengue and coronavirus disease 2019. It is administered through intravenous and subcutaneous (as a lyophilized powder) routes. It is a small molecule heparin sulfate mimetic. The drug candidate acts by targeting heparanase enzyme, VEGF, FGF-1, FGF-2, and TLR9 (toll-like receptor 9). It was also under development for the treatment of solid tumors (subcutaneous route).

Zucero Therapeutics overview

Zucero Therapeutics formerly Zucero Therapeutics Pty Ltd is a biotechnology company, which strives to discover and develop modified sugar compounds for the treatment of cancer. Its pipeline product candidate, PG545 (pixatimod, pINN), a new immunomodulatory agent, stimulates myeloid cells (M1 macrophages and dendritic cells (DC)). Initially, it stimulates the DC, leading to the activation of natural killer (NK) cells that are capable of destroying lymphomas. Next, it blocks tumour-associated macrophages (TAMs), in mouse models, which causes the inhibition of heparanase. PG545 completed a phase Ia clinical trial as a monotherapy in solid tumors and other inflammatory conditions. The company has research office in Darra, Queensland, Australia. Zucero Therapeutics is headquartered in Geelong, Victoria, Australia.

Quick View Pixatimod LOA Data

Report Segments
  • Innovator
Drug Name
  • Pixatimod
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.